NewEdge Wealth LLC Acquires 7,299 Shares of Johnson & Johnson $JNJ

NewEdge Wealth LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% during the 3rd quarter, HoldingsChannel reports. The fund owned 235,947 shares of the company’s stock after buying an additional 7,299 shares during the period. NewEdge Wealth LLC’s holdings in Johnson & Johnson were worth $43,886,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Abich Financial Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the third quarter valued at $26,000. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $27,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson during the third quarter worth approximately $28,000. Semmax Financial Advisors Inc. raised its position in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. Finally, Compass Financial Services Inc lifted its stake in shares of Johnson & Johnson by 707.1% in the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after purchasing an additional 198 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Up 0.6%

Shares of JNJ opened at $244.89 on Thursday. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $246.35. The company’s 50-day moving average price is $219.71 and its 200 day moving average price is $198.21. The firm has a market cap of $590.17 billion, a P/E ratio of 22.16, a price-to-earnings-growth ratio of 2.36 and a beta of 0.35. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion for the quarter. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.1%. Johnson & Johnson’s payout ratio is 47.06%.

Analyst Upgrades and Downgrades

Several research analysts have commented on JNJ shares. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research note on Friday, January 23rd. Royal Bank Of Canada increased their price target on Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. Wolfe Research lifted their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. Finally, Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $233.73.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Announced a >$1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Pennsylvania as part of a multi‑year U.S. manufacturing expansion, signaling long‑term capacity growth for its biologics/cell therapy pipeline. Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
• Positive Sentiment: FDA approved a simplified monthly dosing schedule for RYBREVANT FASPRO (amivantamab + hyaluronidase), improving convenience for EGFR+ NSCLC patients and potentially boosting uptake and product competitiveness. FDA approves RYBREVANT FASPRO as the only EGFR-targeted therapy that can be administered once a month
• Positive Sentiment: Received FDA Breakthrough Therapy Designation for subcutaneous amivantamab (RYBREVANT FASPRO) in advanced head & neck cancer — a regulatory accelerator that can shorten development timelines and enhance commercial prospects if confirmatory data follow. RYBREVANT FASPRO receives U.S. FDA Breakthrough Therapy Designation for head and neck cancer
• Positive Sentiment: Reinforced shareholder returns with a quarterly dividend increase (quarterly payout raised to $1.30), supporting JNJ’s income appeal and dividend‑investor base. Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
• Neutral Sentiment: Options activity has picked up interest around JNJ, which can amplify near‑term moves but doesn’t by itself change fundamentals. Watch for large/ directionally concentrated trades. Behind the Scenes of Johnson & Johnson’s Latest Options Trends
• Neutral Sentiment: Street attention and analyst writeups (Zacks, TipRanks) are keeping JNJ in the spotlight; useful for sentiment tracking but incremental to fundamental drivers. Johnson & Johnson (JNJ) Is a Trending Stock
• Neutral Sentiment: A small contract extension with Trellus Health keeps an adherence/support program in place; operationally positive but immaterial to JNJ’s top line. Trellus Health shares double on J&J extension
• Negative Sentiment: Ongoing talc litigation and recent verdict coverage continue to highlight legal risk and valuation uncertainty, which can cap multiple expansion despite operational positives. Johnson And Johnson Talc Verdict Puts Legal Risks And Valuation In Focus

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.